Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 16/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.47 |
| ▸ | PYGM | P11217 | 10/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941140 | 0.85 | PYGL (0.47) | PYGLSMYD3PYGMHRH4HRH3 | |
| SCHEMBL2941142 | 0.85 | PYGL (0.47) | PYGLSMYD3PYGMHRH4HRH3 | |
| SCHEMBL2938100 | 0.83 | PYGL (0.49) | PYGLSMYD3PYGMHRH4HRH3 | |
| SCHEMBL12035628 | 0.81 | SMYD3 (0.55) | PYGLSMYD3PYGMHRH4HRH3 | |
| SCHEMBL1503788 | 0.80 | SMYD3 (0.54) | PYGLSMYD3PYGMHRH4EHMT2 | |
| SCHEMBL3109143 | 0.80 | SMYD3 (0.52) | PYGLSMYD3EHMT2 | |
| SCHEMBL3079242 | 0.80 | SMYD3 (0.52) | PYGLSMYD3EHMT2 | |
| SCHEMBL12833090 | 0.79 | SMYD3 (0.60) | PYGLSMYD3PYGMHRH4EHMT2 | |
| SCHEMBL2939103 | 0.78 | SMYD3 (0.47) | PYGLSMYD3PYGMHRH4EHMT2 | |
| SCHEMBL4266511 | 0.78 | SMYD3 (0.47) | PYGLSMYD3PYGMHRH4EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | PYGL 4049/4885SMYD3 3311/4885PYGM 4173/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | PYGL 3803/4885SMYD3 3513/4885PYGM 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.